Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
基本信息
- 批准号:10546542
- 负责人:
- 金额:$ 33.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAllelesAnimalsAntisense OligonucleotidesBenignBindingBinding SitesBioinformaticsBiological AssayBirthCardiovascular DiseasesCardiovascular systemCell LineCell ProliferationCellsChemistryClinicalCognitiveCognitive deficitsCommunitiesComplexCutaneousDNA Sequence AlterationDevelopmentDevelopmental Bone DiseasesDiseaseDominant Genetic ConditionsDown-RegulationDrug Delivery SystemsELK1 geneEnzyme-Linked Immunosorbent AssayEvaluationFRAP1 geneFibroblastsFormulationFutureGene ExpressionGene TargetingGenesGenetic DiseasesGenotypeGoalsGrantHeterozygoteIn VitroInnovation CorpsLeadLive BirthLoss of HeterozygosityMAP Kinase GeneMEK inhibitionMalignant NeoplasmsMeasuresMediatingMessenger RNAMethodsMicroRNAsModelingMutateMutationMyeloid CellsNF1 geneNervous system structureNeurofibromatosesNeurofibromatosis 1NucleotidesOther GeneticsPatientsPeer ReviewPersonsPharmaceutical PreparationsPhasePlant RootsPlayPre-Clinical ModelPredispositionProphylactic treatmentProteinsProto-Oncogene Proteins c-aktPublicationsPublishingRAS inhibitionRNARepressionResearchResearch PersonnelReview LiteratureRoleSafetySchwann CellsSeriesSignal PathwaySignal TransductionSiteSkeletonSkinSmall Business Innovation Research GrantSupravalvular aortic stenosisSymptomsTestingThe SunTherapeuticTissuesTransfectionUnited States National Institutes of HealthVertebral columnWestern BlottingWilliams SyndromeWorkYangantagonistassociated symptombasebody systemcancer riskcell typecommercializationdesigndrug developmentdrug discoverygene repressionimprovedin silicoin vitro testingin vivoinduced pluripotent stem cellloss of functionneurofibromanovelphosphorothioatepreventprice listsprogramsprotein expressionsocial deficitssuccesstargeted treatmenttherapeutic candidatetumor
项目摘要
PROJECT ABSTRACT. Neurofibromatosis (NF1) is an autosomal dominant genetic disorder impacting 1 in
3000 births, including over 2M people worldwide, with symptoms including ‘benign’ tumors, bone dysplasia,
cognitive/social deficits, and a very high pre-disposition to both cancers and cardiovascular disease. Current
therapeutic approaches target specific downstream components of NF1 signaling, for example MEK inhibition
in tumors, failing to address the broad range of signaling and symptoms associated with NF1. Given that NF1
is characterized by haploinsufficiency (e.g., lack of functional NF1 protein), and also that miRNA's have been
shown to regulate NF1 protein levels (Paschou 2012; Zhu 2020), we propose here to develop specific RNA-
targeted anti-sense oligonucleotides (ASOs) to promote increased NF1 protein levels, with the goal of
normalizing downstream signaling (Ras, etc.) and thus alleviating NF1 symptoms at the root cause of disease.
We propose this as a novel path of NF1 drug discovery, with potential impact on a broad range of NF1 patients
and symptoms, in a preventative manner, and one that is applicable to the wide spectrum of unique NF1
genetic mutations already identified.
Research Background. Increasing NF1 protein expression via transfection has been shown to reverse
abnormal Ras activation resulting from NF1 protein loss (Wallis, 2018; Mellert, 2018). Also, increased protein
expression in other genetic conditions such as Willams-Beuren Syndrome, and Supravalvular Aortic Stenosis,
compensates for haploinsufficiency (Giordano, 2012). Lastly, overcoming haploinsufficiency in other autosomal
dominant conditions (Sim1; Pax6 genes) has shown an ability in vivo to correct symptoms (Matharu, et. al. 2019;
Rabiee, 2020). NF1 expression is regulated by multiple miRNAs, providing the opportunity to identify and target
miRNAs that regulate NF1 protein expression in key cell types. Development of RNA-targeted ASO’s could lead
to selectively blocking this repression and correcting NF1 haploinsufficiency.
Specific Aims. 1) Using in silico analysis (e.g., TargetScan application and publication reviews) we identify 34
candidate miRNAs, and in SA1 target determining the ability of each to regulate NF1 expression across three
key cell types relevant to NF1. 2) Based on top miRNA candidates, design and validate steric-blocking ASOs
that selectively block miRNA-mediated inhibition of NF1 expression in NF1 disease-relevant cell types. Validate
increased NF1 protein expression across three NF1 relevant cell types. 3) Once increased expression of NF1
protein is established, validate that NF1 steric-blocking ASOs further normalize NF1-dependent signaling utilizing
immortalized Schwann, primary fibroblast and iPSC-derived NF1+/- cells, evaluating the following: a) impact on
Ras/mTOR signaling (pERK, ELK-1, AKT, etc.), and b) impact on cell proliferation. Program goal is to prioritize
2-3 candidate ASOs for an SBIR Phase 2 pre-IND evaluation.
项目摘要。神经纤维瘤病(NF1)是一种常染色体显性遗传疾病,影响1
3000名新生儿,包括全球200多万人,症状包括良性肿瘤,骨发育不良,
认知/社交缺陷,以及癌症和心血管疾病的极高易感性。当前
治疗方法针对NF1信号的特定下游成分,例如MEK抑制
在肿瘤方面,未能解决与NF1相关的广泛信号和症状。鉴于NF1
以单倍体不足为特征(例如,缺乏功能性NF1蛋白),而且miRNA已经
显示调节NF1蛋白水平(Paschou 2012;朱2020),我们在这里建议开发特定的RNA-
靶向反义寡核苷酸(ASO)以促进NF1蛋白水平的增加,目标是
标准化下行信令(RAS等)从而从根本上缓解NF1症状。
我们建议这是一条发现NF1药物的新途径,对广泛的NF1患者具有潜在的影响
和症状,以预防性的方式,并且适用于独特的NF1的广泛范围
已经确定的基因突变。
研究背景。通过转基因增加NF1蛋白的表达已被证明是逆转的
NF1蛋白丢失导致的RAS异常激活(Wallis,2018;Mellert,2018)。此外,蛋白质含量增加
在其他遗传性疾病中的表达,如Willams-Beuren综合征和瓣膜上动脉狭窄,
弥补单倍体不足(佐丹诺,2012)。最后,克服其他常染色体单倍体不足
显性条件(Sim1;Pax6基因)在体内显示出纠正症状的能力(Matharu,et.艾尔2019年;
Rabiee,2020)。NF1的表达受多个miRNAs调控,为识别和靶向提供了机会
在关键细胞类型中调节NF1蛋白表达的miRNAs。以RNA为靶点的ASO的开发可能会引领
选择性地阻断这种抑制并纠正NF1单倍体不足。
明确的目标。1)在计算机分析(例如,TargetScan应用程序和出版评论)中,我们确定了34
候选miRNAs,并在SA1靶标中确定每个miRNAs调控NF1表达的能力
与NF1相关的关键细胞类型。2)基于热门的miRNA候选序列,设计并验证空间阻断ASO
选择性地阻断miRNA介导的对NF1疾病相关细胞类型中NF1表达的抑制。验证
NF1蛋白在三种NF1相关细胞类型中的表达增加。3)一旦NF1表达增加
蛋白质被建立,验证NF1空间阻断ASO进一步正常化NF1依赖的信号利用
永生化雪旺细胞、原代成纤维细胞和IPSC来源的NF1+/-细胞,评估以下影响:a)
RAS/mTOR信号(PERK、ELK-1、AKT等),以及b)对细胞增殖的影响。计划目标是确定优先顺序
2-3个候选ASO进行SBIR第二阶段IND前评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle Mattson-Hoss其他文献
Michelle Mattson-Hoss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle Mattson-Hoss', 18)}}的其他基金
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10844204 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10752193 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10789739 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency
抑制 NF1 蛋白降解作为 NF1 单倍体不足的治疗方法
- 批准号:
10325710 - 财政年份:2021
- 资助金额:
$ 33.95万 - 项目类别:
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency
抑制 NF1 蛋白降解作为 NF1 单倍体不足的治疗方法
- 批准号:
10490386 - 财政年份:2021
- 资助金额:
$ 33.95万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 33.95万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 33.95万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 33.95万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 33.95万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 33.95万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 33.95万 - 项目类别: